

PROGRAM



AF-SCREEN

www.afscreen.org



11th international collaboration meeting and 4th round table

August 27, 2026

Friedrich-von-Gaertner lecture hall University Hospital Munich Germany

In collaboration with :



www.tmacademy.org





Program

11th international collaboration meeting and 4th round table

August 27, 2026

Friedrich-von-Gaertner lecture hall University
Hospital Munich Germany

- 1 | **Atrial myopathy: definition, diagnosis, and mechanisms: PI3K , Adipokines, Inflammation, IGF1R**

- 2 | **Personalised and targeted screening for AF: Routine clinic/hospital/primary care records, biochemistry, genetics, ECG, AI or just age**

- 3 | **Screening for AF in HFPEF and screening for HFPEF in AF**

- 4 | **Next "White Paper" : AF and HFPEF: exploration in depth from leads of our State of Art Review**

- 5 | **What the guidelines say about Device-detected AF and wearable-detected AF**

- 6 | **How will AF BURDEN be incorporated in AF screening and AF management**

- 7 | **Progress on AF screening RCTs . When will we know the answer ?**

- 8 | **Combined Hypertension and AF screening. Progress of collaboration with MMM**

- 9 | **Role of Hypertension control in management of AF burden, minimization of AF progression and progress to HFPEF**

- 10 | **Update of post-stroke management after OCEANIC-STROKE trial**
 - a. What type of search for AF? how long, what methods, role of diagnosis of Atrial Cardiomyopathy

- 11 | **Impact of safer anticoagulants on management of Screen-detected AF**

- 12 | **What comes next after AF ablation**
 - a. How much AF monitoring is needed, and which method?
 - b. DOACs for whom, how long or pill in the pocket?
 - c. Role of LAAO device placement?

- 13 | **Beyond DOACs: The Role of LAAO**
 - a. Do we still need antithrombotic therapies after LAA Occlusion device placement